FORMULIERUNG MIT CERALASERTIB
European patent · EP4312993 · In force
Register entry
- Publication number
- EP4312993
- Application number
- EP22717111
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Mar 21, 2022
- Published
- Feb 7, 2024
- Granted
- Oct 8, 2025
- Protection ends at the latest
- Mar 20, 2042
- Next annual fee due
- Mar 31, 2027
- IPC classes
- A61K 9/20 (2006.01)A61K 31/5377 (2006.01)A61P 35/00 (2006.01)
- Priority
- WO PCT/CN2021/081978 22.03.2021
- PCT application
- PCT/EP2022/057305 21.03.2022
- PCT publication
- WO2022/200251 29.09.2022
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Aug 19, 2026
Change
Published in Swissreg on 19.08.2026
- Apr 1, 2026
Next annual fee due on
- Next annual fee due on
- 31.03.2026 → 31.03.2027
Published in Swissreg on 01.04.2026
- Jan 8, 2026
Agent entered
- Representative
- Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex
Published in Swissreg on 08.01.2026
- Oct 8, 2025
Granted
- Specification status
- Non-published patent application → Granted patent
- Status of protective title
- Initiated → Active
Published in Swissreg on 08.10.2025
Parties
Inventor
SIMPSON, David Bradley Brook
Cambridge Cambridgeshire CB2 0AA, GB
REN, Haixia
Shanghai, CN
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.